» Articles » PMID: 38186661

Cardiovascular Disease Outcomes Among Established Cigar Users 40 years and Older: Findings from the Population Assessment of Tobacco and Health (PATH) Study, Waves 1-5 (2013-2019)

Abstract

This study examined associations between established cigar use and prevalence and incidence of cardiovascular diseases (CVD; congestive heart failure, stroke, or heart attack/needed bypass surgery) among U.S. adults, 40 years or older. Using Waves 1-5 (2013-2019) of the Population Assessment of Tobacco and Health (PATH) Study, incidence (N (N) = 6,692; N (N) = 23,738) and prevalence (N = 7,819; N = 33,952) of CVD outcomes were examined using weighted generalized estimating equations (WGEEs) among adults who were exclusive current/former established cigar smokers (ever cigar smokers who have smoked fairly regularly), exclusive current/former established cigarette smokers (lifetime smokers of 100 or more cigarettes), dual current/former established cigarette and cigar smokers compared with never smokers of cigars or cigarettes, adjusting for covariates. The population-averaged incidence of CVD from one wave to next among exclusive current/former established cigar smokers during a six-year period based on WGEEs was low (overall average rate of 3.0 %; 95 % CI: 1.2, 7.0). Compared with never users, exclusive current/former established cigar smokers (OR = 1.67, 95 % CI: 1.11, 2.51) and exclusive current/former established cigarette smokers (OR = 2.12, 95 % CI: 1.45, 3.09) were more likely to have any CVD outcome in unadjusted analyses. When adjusted for covariates, only exclusive current/former established cigarette use was associated with CVD outcomes (AOR = 1.60, CI: 1.07, 2.40). Results suggest that exclusive established use of cigars or duration of exclusive cigar use was not associated with lifetime CVD prevalence compared with never cigar or cigarette smokers, which is important in understanding health outcomes in cigar users.

Citing Articles

The Public Health Impact of a Ban on Flavored Cigars: A Decision-Theoretic Policy Framework.

Levy D, Cadham C, Mok Y, Travis N, Buszkiewicz J, Jeon J Nicotine Tob Res. 2024; 27(2):333-341.

PMID: 39001665 PMC: 11750745. DOI: 10.1093/ntr/ntae173.


A Longitudinal Analysis of Flavored Cigar Use and Cigar Smoking Cessation Among US Adults.

Buszkiewicz J, Cook S, Oh H, Mukerjee R, Hirschtick J, Fleischer N Nicotine Tob Res. 2023; 26(7):816-825.

PMID: 38141259 PMC: 11190056. DOI: 10.1093/ntr/ntad256.

References
1.
Rostron B, Corey C, Gindi R . Cigar smoking prevalence and morbidity among US adults, 2000-2015. Prev Med Rep. 2019; 14:100821. PMC: 6378850. DOI: 10.1016/j.pmedr.2019.100821. View

2.
McCarthy P . Pseudoreplication: further evaluation and applications of the balanced half-sample technique. Vital Health Stat 2. 1969; (31):1-24. View

3.
Mahoney M, Rivard C, Hammad H, Blanco C, Sargent J, Kimmel H . Cardiovascular Risk Factor and Disease Measures from the Population Assessment of Tobacco and Health (PATH) Study. Int J Environ Res Public Health. 2021; 18(14). PMC: 8305887. DOI: 10.3390/ijerph18147692. View

4.
Lubin J, Couper D, Lutsey P, Woodward M, Yatsuya H, Huxley R . Risk of Cardiovascular Disease from Cumulative Cigarette Use and the Impact of Smoking Intensity. Epidemiology. 2016; 27(3):395-404. PMC: 5482174. DOI: 10.1097/EDE.0000000000000437. View

5.
Christensen C, Rostron B, Cosgrove C, Altekruse S, Hartman A, Gibson J . Association of Cigarette, Cigar, and Pipe Use With Mortality Risk in the US Population. JAMA Intern Med. 2018; 178(4):469-476. PMC: 5876825. DOI: 10.1001/jamainternmed.2017.8625. View